Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study
We performed a prospective study to examine the genetic effect on the response to a calcium (Ca) channel blocker, azelnidipine and an ACE inhibitor, temocapril treatment in patients with hypertension, as a part of the prior clinical trial, the Azelnidipine and Temocapril in Hypertensive Patients wit...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | International Journal of Hypertension |
| Online Access: | http://dx.doi.org/10.4061/2010/196307 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556235871748096 |
|---|---|
| author | Ken Sugimoto Tomohiro Katsuya Kei Kamide Tomomi Fujisawa Izumi Shimaoka Mitsuru Ohishi Ryuichi Morishita Toshio Ogihara Hiromi Rakugi |
| author_facet | Ken Sugimoto Tomohiro Katsuya Kei Kamide Tomomi Fujisawa Izumi Shimaoka Mitsuru Ohishi Ryuichi Morishita Toshio Ogihara Hiromi Rakugi |
| author_sort | Ken Sugimoto |
| collection | DOAJ |
| description | We performed a prospective study to examine the genetic effect on the response to a calcium (Ca) channel blocker, azelnidipine and an ACE inhibitor, temocapril treatment in patients with hypertension, as a part of the prior clinical trial, the Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study (ATTEST).
Methods and Results. All subjects who gave informed consent for genetic research were divided into two groups: the subjects treated with azelnidipine or temocapril, for 52 weeks. We selected 18 susceptible genes for hypertension and determined their genotypes using TaqMan PCR method. RNA samples were extracted from peripheral blood, and quantitative real time PCR for all genes was performed using TaqMan method. One of the polymorphisms of the RGS2 gene was extracted as being able to influence the effect of these treatments to reduce BP. At eight weeks, BP change showed a significant interaction between the A-638G polymorphism of Regulator of G protein signaling-2 (RGS2) gene and treatment with azelnidipine or temocapril. There was no gene whose expression was associated with BP phenotypes or the polymorphisms of each gene.
Conclusions. A-638G polymorphism of the RGS-2 gene could be a predictive factor for therapeutic performance of Ca channel blockers. |
| format | Article |
| id | doaj-art-f6655bbdc46c4462adcd717ce7a2e93b |
| institution | Kabale University |
| issn | 2090-0392 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hypertension |
| spelling | doaj-art-f6655bbdc46c4462adcd717ce7a2e93b2025-02-03T05:46:06ZengWileyInternational Journal of Hypertension2090-03922010-01-01201010.4061/2010/196307196307Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes StudyKen Sugimoto0Tomohiro Katsuya1Kei Kamide2Tomomi Fujisawa3Izumi Shimaoka4Mitsuru Ohishi5Ryuichi Morishita6Toshio Ogihara7Hiromi Rakugi8Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, 2-2 B6, Yamada-oka, Suita, Osaka 565-0871, JapanDepartment of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka 565-0871, JapanDepartment of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, 2-2 B6, Yamada-oka, Suita, Osaka 565-0871, JapanDepartment of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, 2-2 B6, Yamada-oka, Suita, Osaka 565-0871, JapanDepartment of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, 2-2 B6, Yamada-oka, Suita, Osaka 565-0871, JapanDepartment of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, 2-2 B6, Yamada-oka, Suita, Osaka 565-0871, JapanDepartment of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka 565-0871, JapanOsaka General Medical Center, Osaka Prefectural Hospital Organization, Osaka, JapanDepartment of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, 2-2 B6, Yamada-oka, Suita, Osaka 565-0871, JapanWe performed a prospective study to examine the genetic effect on the response to a calcium (Ca) channel blocker, azelnidipine and an ACE inhibitor, temocapril treatment in patients with hypertension, as a part of the prior clinical trial, the Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study (ATTEST). Methods and Results. All subjects who gave informed consent for genetic research were divided into two groups: the subjects treated with azelnidipine or temocapril, for 52 weeks. We selected 18 susceptible genes for hypertension and determined their genotypes using TaqMan PCR method. RNA samples were extracted from peripheral blood, and quantitative real time PCR for all genes was performed using TaqMan method. One of the polymorphisms of the RGS2 gene was extracted as being able to influence the effect of these treatments to reduce BP. At eight weeks, BP change showed a significant interaction between the A-638G polymorphism of Regulator of G protein signaling-2 (RGS2) gene and treatment with azelnidipine or temocapril. There was no gene whose expression was associated with BP phenotypes or the polymorphisms of each gene. Conclusions. A-638G polymorphism of the RGS-2 gene could be a predictive factor for therapeutic performance of Ca channel blockers.http://dx.doi.org/10.4061/2010/196307 |
| spellingShingle | Ken Sugimoto Tomohiro Katsuya Kei Kamide Tomomi Fujisawa Izumi Shimaoka Mitsuru Ohishi Ryuichi Morishita Toshio Ogihara Hiromi Rakugi Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study International Journal of Hypertension |
| title | Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study |
| title_full | Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study |
| title_fullStr | Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study |
| title_full_unstemmed | Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study |
| title_short | Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study |
| title_sort | promoter polymorphism of rgs2 gene is associated with change of blood pressure in subjects with antihypertensive treatment the azelnidipine and temocapril in hypertensive patients with type 2 diabetes study |
| url | http://dx.doi.org/10.4061/2010/196307 |
| work_keys_str_mv | AT kensugimoto promoterpolymorphismofrgs2geneisassociatedwithchangeofbloodpressureinsubjectswithantihypertensivetreatmenttheazelnidipineandtemocaprilinhypertensivepatientswithtype2diabetesstudy AT tomohirokatsuya promoterpolymorphismofrgs2geneisassociatedwithchangeofbloodpressureinsubjectswithantihypertensivetreatmenttheazelnidipineandtemocaprilinhypertensivepatientswithtype2diabetesstudy AT keikamide promoterpolymorphismofrgs2geneisassociatedwithchangeofbloodpressureinsubjectswithantihypertensivetreatmenttheazelnidipineandtemocaprilinhypertensivepatientswithtype2diabetesstudy AT tomomifujisawa promoterpolymorphismofrgs2geneisassociatedwithchangeofbloodpressureinsubjectswithantihypertensivetreatmenttheazelnidipineandtemocaprilinhypertensivepatientswithtype2diabetesstudy AT izumishimaoka promoterpolymorphismofrgs2geneisassociatedwithchangeofbloodpressureinsubjectswithantihypertensivetreatmenttheazelnidipineandtemocaprilinhypertensivepatientswithtype2diabetesstudy AT mitsuruohishi promoterpolymorphismofrgs2geneisassociatedwithchangeofbloodpressureinsubjectswithantihypertensivetreatmenttheazelnidipineandtemocaprilinhypertensivepatientswithtype2diabetesstudy AT ryuichimorishita promoterpolymorphismofrgs2geneisassociatedwithchangeofbloodpressureinsubjectswithantihypertensivetreatmenttheazelnidipineandtemocaprilinhypertensivepatientswithtype2diabetesstudy AT toshioogihara promoterpolymorphismofrgs2geneisassociatedwithchangeofbloodpressureinsubjectswithantihypertensivetreatmenttheazelnidipineandtemocaprilinhypertensivepatientswithtype2diabetesstudy AT hiromirakugi promoterpolymorphismofrgs2geneisassociatedwithchangeofbloodpressureinsubjectswithantihypertensivetreatmenttheazelnidipineandtemocaprilinhypertensivepatientswithtype2diabetesstudy |